COMP360 Nears FDA Filing on Acute Benefit but Durability and Precedent Gaps Persist

Compass Pathways Nears FDA Filing for COMP360 Amidst Competitive Landscape

Compass Pathways is nearing FDA submission for its psilocybin drug, COMP360, for treatment-resistant depression, with filing expected within two weeks and launch in the first half of 2027. This update follows market volatility triggered by news of Usona Institute's own psilocybin candidate submission for major depressive disorder. Both companies hold Commissioner’s National Priority Vouchers (CNPVs), which could expedite the FDA review period to 1-2 months. Compass's stock initially dipped due to competitive concerns but rebounded after its Q3 earnings report, with analysts suggesting the market is large enough for multiple competitors.

• Compass Pathways' stock experienced a significant dip of over 35% following reports of Usona Institute's FDA submission for its psilocybin candidate, PSIL201, for MDD. Despite this, analysts from RBC Capital Markets viewed the dip as a buying opportunity, citing the large market size for depression treatments that could accommodate multiple competitors. Compass's shares partially rebounded after its third-quarter earnings announcement.
• Both Compass Pathways' COMP360 and Usona Institute's PSIL201 have been granted Commissioner’s National Priority Vouchers (CNPVs) by the FDA. This designation is crucial as it significantly shortens the standard drug review period from 10-12 months to an accelerated 1-2 months, increasing confidence in COMP360's potential approval within the first quarter of 2027, if not earlier.
• Compass Pathways emphasized the differentiated nature of its COMP360 data, which targets a highly refractory treatment-resistant depression (TRD) population. In the Phase 3 COMP006 trial, 39% of TRD patients achieved a clinically meaningful reduction in depression severity by week six, maintaining a durable response through week 26 with a comparable safety profile. This contrasts with Usona's PSIL201, which showed rapid and sustained antidepressant effects in a Phase 2 MDD trial.

Addressing the Unmet Needs in Treatment-Resistant Depression

Treatment-resistant depression remains a major clinical challenge associated with persistent functional impairment, increased morbidity, reduced quality of life, and greater healthcare utilization. While conventional therapies remain central to management, newer modalities have expanded options, yet significant limitations persist around durability, accessibility, and long-term outcomes.

• Lack of standardized definition and sequencing: There is a need to establish agreement on a standardized, systematic, and feasible definition of TRD, commonly defined as failure to achieve remission after at least two adequately conducted antidepressant trials, with continued research needed to better define treatment sequencing and improve management strategies based on patient characteristics, prior treatment response, and illness severity.

• Poor remission and high relapse with guideline-practice gap: Remission was recorded in 42% patients with MDD and 13% with TRD, whereas relapse was seen in 20 970 (21%) and 4923 (54%), respectively, with long-term treatment with single antidepressants highlighting the difference between treatment guidelines and reality of clinical practice and the need to optimise treatment pathways and access to newer therapies.

• Durability, cost, accessibility and long-term uncertainty: Significant limitations remain, including cost, accessibility, durability of response, and uncertainty regarding long-term outcomes and side effects, with a need to establish safety and tolerability beyond acute treatment phase.

• Residual symptoms and tolerability burden: Incomplete remission is associated with poor outcomes including higher risk of relapse and chronicity, with most common residual symptoms being sleep disturbances, fatigue, and disinterest; most current treatments fail to adequately address sleep disturbances and may even aggravate them, while weight gain and sexual dysfunction may also reduce the quality of remission.

• Limited personalization and differential response: There is a need to establish individual psychosocial and neurobiological marks such as pharmacogenetic variance, and patients with ANX-TRD were less likely to respond to a single low-dose ketamine infusion than those with NANX-TRD, with ketamine superior to placebo for reducing depressive symptoms in NANX-TRD but not superior to placebo in ANX-TRD.

COMP360's Safety and Efficacy Profile for TRD

In adult females with anorexia nervosa, oral psilocybin (COMP360) administered over 6 weeks in a fixed order (1 mg, 25 mg, 25 mg), alongside talk therapy and adjunctive to treatment as usual, was well tolerated by all 21 participants. The most common adverse events were headache, nausea and dizziness. Two serious adverse events (suicide attempts) were reported for one participant within the 6-12-month period.

In adults with post-traumatic stress disorder receiving a single 25 mg dose of COMP360 psilocybin with psychological support, amongst the 22 participants enrolled there was a total of 117 treatment-emergent adverse events (TEAEs); 70 (59.8%) were reported on administration day, of which 64/70 (91.4%) resolved by the end of the next day. TEAEs commonly included headache (n = 11; 50.0%), nausea (n = 8; 36.4%), crying (n = 6; 27.3%) and fatigue (n = 6; 27.3%). There were no serious TEAEs or TEAEs leading to study withdrawal.

In treatment-resistant depression, 19 participants dosed with a single 25 mg dose of synthetic psilocybin (investigational drug COMP360) adjunct to a selective serotonin reuptake inhibitor alongside psychological support showed Twelve (63.2%) participants with a TEAE, most of which were mild and resolved on the day of onset. There were no serious TEAEs or indication of increased suicidal ideation or behavior. In COMP 004, a 52-week observational follow-up of patients from COMP 001 and COMP 003, few AEs were reported post-entry into COMP 004, with 1 AE of mild suicidal ideation in the 1 mg group deemed possibly related to study drug.

The Evolving Psychedelic Therapy Landscape for Depression

COMP360 is a synthetic form of psilocybin investigated adjunct to a selective serotonin reuptake inhibitor in participants with treatment-resistant depression (TRD). Classical psychedelics such as psilocybin and N,N-dimethyltryptamine (DMT) act primarily as 5-hydroxytryptamine 2A (5-HT) receptor agonists. Other serotoninergic psychedelics with trials in TRD or major depressive disorder (MDD) include LSD, DMT, ayahuasca, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), mescaline (3,4,5-trimethoxyphenethylamine) and GM-2505.